Key result
LCZ696 reduced the composite risk of cardiovascular death or first hospitalization for heart failure by 20% (HR 0.80) compared to enalapril in patients with heart failure and reduced ejection fraction.
Why the study?
Does LCZ696 (sacubitril/valsartan) reduce the composite of cardiovascular death or first hospitalization for heart failure in patients with HFrEF compared to enalapril?
Does LCZ696 (sacubitril/valsartan) reduce the composite of cardiovascular death or first hospitalization for heart failure in patients with HFrEF compared to enalapril?
Hazard Ratio: 0.8 (95% CI 0.73–0.87)
Absolute Event Rate: 21.8% vs 26.5%
Number Needed to Treat: 21
p-value: p=0.0000002
LCZ696 (sacubitril/valsartan) is superior to enalapril in reducing the risks of cardiovascular death and heart failure hospitalization in patients with HFrEF.
This editorial summarises important findings from the PARADIGM-HF study. PARADIGM-HF indicated that the angiotensin receptorneprilysin inhibitor, LCZ696, is superior to enalapril in reducing the risks of cardiovascular death and of hospitalisation for heart failure in patients with heart failure and reduced ejection fraction.
No takes yet. Share an insight, caveat, or question.
José Silva‐Cardoso (2016) conducted an editorial in Heart failure with reduced ejection fraction (n=8,442). LCZ696 vs. Enalapril 10 mg twice daily was evaluated on Composite of death from cardiovascular causes or a first hospitalisation for heart failure (HR 0.80, 95% CI 0.73-0.87, p=0.0000002). LCZ696 reduced the composite risk of cardiovascular death or first hospitalization for heart failure by 20% (HR 0.80) compared to enalapril in patients with heart failure and reduced ejection fraction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: